Oak Therapeutics, Inc.
Publicly observedLawrence, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Lawrence | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Oak Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | SJ7GGFACQTJ5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Sept 2023Publicly observed
NIH SBIR/STTR award: Oral Dissolvable Strips (ODS) as new pediatric and adult delivery mode of therapy for latent tuberculosis
USD 814,340.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2023Publicly observed
NIH SBIR/STTR award: Oral Dissolvable Strips (ODS) as new pediatric and adult delivery mode of therapy for latent tuberculosis
USD 892,787.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2022Publicly observed
NIH SBIR/STTR award: Novel antiretroviral therapy delivery platform for infants and young children: oral dispensable strips (ODS)
USD 899,010.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.